Tuesday, June 7, 2016

UPDATE 2-Sarepta says FDA asks for more data for its muscle-wasting treatment

June 6 (Reuters) - Sarepta Therapeutics Inc said

the U.S. Food and Drug Administration has requested for

additional data from an ongoing study for its muscle-wasting

treatment as the agency decides...

Read more

No comments:

Post a Comment